{"id":"bexxar","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00950755","NCT00770224","NCT00078598","NCT00004874","NCT00933335","NCT00110071","NCT00996996","NCT00022906","NCT00490490","NCT00107380","NCT00022945","NCT00315731","NCT00062894","NCT00006695","NCT00240591","NCT01224821","NCT00268203","NCT00003784","NCT00434629","NCT00416312","NCT00268983","NCT00073931","NCT00992992","NCT00484874","NCT00577629","NCT00475332","NCT00777114","NCT00022893","NCT01536561","NCT00479167","NCT00319332","NCT00329030","NCT00135200","NCT00240578","NCT00476047","NCT00240565","NCT00574509","NCT00022932","NCT01868035","NCT00022958","NCT01573000","NCT00006721","NCT00490009","NCT01484093","NCT01663714","NCT00073918","NCT00989664","NCT01389076","NCT00022880","NCT00996593"],"aliases":["Tositumomab","iodine-131 tositumomab","I-131 tositumomab","Iodine I 131 tositumomab"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Bexxar","companyId":"susan-knox","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Susan Knox","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Bexxar","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00950755","phase":"Phase 2","title":"Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":41,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2011-04"},{"nctId":"NCT00770224","phase":"Phase 2","title":"A Phase II Study of Iodine-131-Labeled Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients With Advanced Stage Follicular Non-Hodg","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","isPivotal":false,"enrollment":87,"indication":"Lymphoma","completionDate":"2019-08"},{"nctId":"NCT00078598","phase":"Phase 3","title":"A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Corixa Corporation","isPivotal":true,"enrollment":506,"indication":"Non-Hodgkin's Lymphoma","completionDate":""},{"nctId":"NCT00004874","phase":"Phase 3","title":"Expanded Access Study of Iodine-131 Anti-B1 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"University of Nebraska","isPivotal":true,"enrollment":31,"indication":"Lymphoma","completionDate":"2012-11"},{"nctId":"NCT00933335","phase":"Phase 2","title":"Fludarabine Monophosphate Followed by Iodine I 131 Tositumomab for Untreated Low-grade and Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":38,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2010-08"},{"nctId":"NCT00110071","phase":"Phase 1","title":"A Clinical Trial Evaluating I131-Tositumomab (Anti-CD20) With Escalating Doses of Fludarabine Followed by Autologous or Syngeneic Stem Cell Transplantation for Relapsed or Refractory B-cell Non-Hodgki","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","isPivotal":false,"enrollment":38,"indication":"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma","completionDate":""},{"nctId":"NCT00996996","phase":"Phase 2","title":"Phase II Trial of Iodine-131 Anti-B1 Antibody for Previously Untreated, Advanced Stage, Low Grade Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":77,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2011-10"},{"nctId":"NCT00022906","phase":"Phase 1","title":"Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody For Patients With Previously Treated Non-Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement","status":"UNKNOWN","sponsor":"Corixa Corporation","isPivotal":false,"enrollment":24,"indication":"Non-Hodgkin's Lymphoma","completionDate":""},{"nctId":"NCT00490490","phase":"Phase 2","title":"Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Stanford University","isPivotal":false,"enrollment":8,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2013-07"},{"nctId":"NCT00107380","phase":"Phase 2","title":"Iodine-131-Labeled Monoclonal Anti-B1 Antibody (I-131 Tositumomab) in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients ≥ Age 60 With Advanced ","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","isPivotal":false,"enrollment":86,"indication":"Lymphoma","completionDate":"2015-12"},{"nctId":"NCT00022945","phase":"Phase 2","title":"Phase II Study Of Iodine-131 Anti-B1 Antibody Plus CHOP For Patients With Previously Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Corixa Corporation","isPivotal":false,"enrollment":0,"indication":"Mantle Cell Lymphoma","completionDate":""},{"nctId":"NCT00315731","phase":"Phase 1","title":"A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":15,"indication":"Lymphoma, Follicular","completionDate":"2013-06-30"},{"nctId":"NCT00062894","phase":"Phase 1","title":"A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":12,"indication":"Non-Hodgkin's Lymphoma","completionDate":"2007-04"},{"nctId":"NCT00006695","phase":"Phase 2","title":"BEAM Plus Iodine-131 Anti-B1 Antibody and Autologous Hematopoietic Stem Cell Transplantation for Treatment of Recurrent Diffuse Large B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","isPivotal":false,"enrollment":50,"indication":"Lymphoma","completionDate":"2014-12-16"},{"nctId":"NCT00240591","phase":"N/A","title":"A MULTI-CENTER LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH LOW-GRADE NON-HODGKIN'S LYMPHOMA PREVIOUSLY TREATED WITH TOSITUMOMAB AND/OR IODINE I 131 TOSITUMOMAB IN STUDIES RIT-I-000, RIT-II-001, RIT-II-","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":150,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2010-06"},{"nctId":"NCT01224821","phase":"Phase 2","title":"Multicenter, Phase II Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed t","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":47,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2008-05"},{"nctId":"NCT00268203","phase":"Phase 2","title":"Expanded Access Study of Iodine I 131 Tositumomab for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":765,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2013-02"},{"nctId":"NCT00003784","phase":"Phase 2","title":"A Phase II Pilot Trial of CHOP Followed by Iodine-131-Labeled Monoclonal Anti-B1 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","isPivotal":false,"enrollment":102,"indication":"Lymphoma","completionDate":""},{"nctId":"NCT00434629","phase":"Phase 1","title":"A Phase I Study of Bexxar® (Tositumomab and 131I-Tositumomab) Radioimmunotherapy in Patients With Relapsed or Residual CD20 Antigen-Expressing B-Cell Lymphomas Following Autologous Hematopoietic Stem ","status":"COMPLETED","sponsor":"University of Pennsylvania","isPivotal":false,"enrollment":16,"indication":"B-cell Lymphoma, Non-Hodgkin's Lymphoma","completionDate":"2015-05"},{"nctId":"NCT00416312","phase":"N/A","title":"Dose-Response in Radioimmunotherapy of Lymphoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","isPivotal":false,"enrollment":9,"indication":"Lymphoma","completionDate":"2009-10"},{"nctId":"NCT00268983","phase":"Phase 3","title":"A Multi-Center, Randomized, Phase 3 Study of Rituximab Versus Iodine I 131 Tositumomab Therapeutic Regimen For Patients With Relapsed Follicular Non-Hodgkins Lymphoma","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":14,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2013-06"},{"nctId":"NCT00073931","phase":"Phase 2","title":"A Phase II Trial Evaluating: Radioiodinated Anti-B1 (Anti-CD20) Antibody With Autologous Stem Cell Transplantation For Relapsed Or Refractory Non-Hodgkin's Lymphoma In Patients 60 Years Of Age And Old","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","isPivotal":false,"enrollment":25,"indication":"Lymphoma","completionDate":"2014-07"},{"nctId":"NCT00992992","phase":"Phase 2","title":"Phase II Study Of Iodine-131 Anti-B1 Antibody Plus CHOP For Patients With Previously Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":25,"indication":"Lymphoma, Mantle-Cell","completionDate":"2013-06-30"},{"nctId":"NCT00484874","phase":"Phase 1","title":"A Phase I/II Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","isPivotal":false,"enrollment":12,"indication":"Hodgkin's Disease","completionDate":"2015-11"},{"nctId":"NCT00577629","phase":"Phase 2","title":"Dose-Intensive Chemotherapy Combined With Monoclonal Antibody Therapy and Targeted Radioimmunotherapy for Untreated Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Duke University","isPivotal":false,"enrollment":39,"indication":"Lymphoma, B-Cell","completionDate":"2016-11-03"},{"nctId":"NCT00475332","phase":"Phase 2","title":"Feasibility Study of External Beam Radiotherapy and Iodine-131 Tositumomab (Bexxar) for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"University of Florida","isPivotal":false,"enrollment":2,"indication":"Non-Hodgkin's Lymphoma, Follicular Lymphoma","completionDate":"2009-04"},{"nctId":"NCT00777114","phase":"Phase 1","title":"Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","isPivotal":false,"enrollment":31,"indication":"Non-Hodgkin's Lymphoma","completionDate":"2012-12-18"},{"nctId":"NCT00022893","phase":"NA","title":"Retreatment Study of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti-B1 Antibody.","status":"UNKNOWN","sponsor":"Corixa Corporation","isPivotal":false,"enrollment":0,"indication":"Non-Hodgkin's Lymphoma","completionDate":""},{"nctId":"NCT01536561","phase":"Phase 1","title":"Phase I Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":59,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2009-10-16"},{"nctId":"NCT00479167","phase":"Phase 2","title":"A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodg","status":"TERMINATED","sponsor":"Rush University Medical Center","isPivotal":false,"enrollment":1,"indication":"Follicular Lymphoma","completionDate":"2008-09"},{"nctId":"NCT00319332","phase":"Phase 3","title":"A Multi-center, Randomized, Phase 3 Study of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen for Patients With Relapsed or Transformed Follicular Non-Hodgk","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":0,"indication":"Lymphoma, Small Cleaved-Cell, Follicular, Lymphoma, Large-Cell, Follicular","completionDate":"2021-02"},{"nctId":"NCT00329030","phase":"Phase 3","title":"Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMT","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","isPivotal":true,"enrollment":224,"indication":"Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic","completionDate":"2013-08"},{"nctId":"NCT00135200","phase":"Phase 2","title":"A Phase II Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","isPivotal":false,"enrollment":16,"indication":"Multiple Myeloma","completionDate":"2024-09-04"},{"nctId":"NCT00240578","phase":"N/A","title":"A MULTI-CENTER LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH LOW-GRADE NON-HODGKIN'S LYMPHOMA PREVIOUSLY TREATED WITH IODINE I 131 TOSITUMOMAB IN STUDIES CP-97-011, CP-98-025, CP-99-032, or CP-99-036","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":88,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2013-06"},{"nctId":"NCT00476047","phase":"Phase 2","title":"A Study of 131I-Tositumomab (Bexxar®) Consolidation in Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","isPivotal":false,"enrollment":16,"indication":"Lymphoid Leukemia in Remission, Stage I Chronic Lymphocytic Leukemia","completionDate":"2015-02"},{"nctId":"NCT00240565","phase":"Phase 2","title":"A Single Arm, Open-label, Multicentre, Phase II Study of Tositumomab and Iodine 131-Tositumomab in Subjects With Indolent Non-Hodgkin's Lymphoma Who Have Previously Received Rituximab.","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":93,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2011-09"},{"nctId":"NCT00574509","phase":"Phase 1","title":"BEAM + 131Iodine-Anti-B1 Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Recurrent Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","isPivotal":false,"enrollment":34,"indication":"Lymphoma","completionDate":"2014-12-10"},{"nctId":"NCT00022932","phase":"Phase 2","title":"Phase II Multicenter Study of Iodine-131 Anti-B1 Antibody Consolidation For Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Following First-Line CHOP","status":"UNKNOWN","sponsor":"Corixa Corporation","isPivotal":false,"enrollment":0,"indication":"Non-Hodgkin's Lymphoma","completionDate":""},{"nctId":"NCT01868035","phase":"Phase 2","title":"Phase II Multicenter Study of Iodine-131 Anti-B1 Antibody Consolidation For Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Following First-line CHOP","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":15,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2012-10"},{"nctId":"NCT00022958","phase":"NA","title":"Expanded Access Study of Iodine-131 Anti-B1 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Corixa Corporation","isPivotal":false,"enrollment":0,"indication":"Non-Hodgkin's Lymphoma","completionDate":""},{"nctId":"NCT01573000","phase":"Phase 2","title":"Phase II a Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":78,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2010-04"},{"nctId":"NCT00006721","phase":"Phase 3","title":"A Phase III Trial of CHOP Plus Rituximab vs CHOP Plus Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","isPivotal":true,"enrollment":571,"indication":"Lymphoma","completionDate":"2025-12"},{"nctId":"NCT00490009","phase":"Phase 2","title":"Phase 2 Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma (DLCL)","status":"COMPLETED","sponsor":"Susan Knox","isPivotal":false,"enrollment":9,"indication":"Lymphoma","completionDate":"2013-06"},{"nctId":"NCT01484093","phase":"Phase 1","title":"Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma: A Phase I/II Trial","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":96,"indication":"Mantle Cell Lymphoma","completionDate":"2023-08-11"},{"nctId":"NCT01663714","phase":"Phase 2","title":"Phase II Multicenter Study of Cyclophosphamide, Vincristine, and Prednisone (CVP) Followed by Iodine-131 Anti-B1 Antibody for Patients With Untreated Low-grade Non-Hodgkin's Lymphoma (NHL).","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":30,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2012-02"},{"nctId":"NCT00073918","phase":"Phase 2","title":"A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgk","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","isPivotal":false,"enrollment":111,"indication":"Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma","completionDate":"2011-10-02"},{"nctId":"NCT00989664","phase":"Phase 2","title":"Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to ","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":60,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2008-09"},{"nctId":"NCT01389076","phase":"Phase 2","title":"Phase II Trial of Low-Dose Methotrexate and Iodine I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","isPivotal":false,"enrollment":22,"indication":"Follicular Lymphoma","completionDate":"2016-06"},{"nctId":"NCT00022880","phase":"Phase 1","title":"A Phase I, Dose-Escalation, Open-Label, Multicenter Study of Iodine-131, Anti-B1 Antibody for Intermediate- and High-Risk B-Cell Chronic Lymphocytic Leukemia","status":"UNKNOWN","sponsor":"Corixa Corporation","isPivotal":false,"enrollment":30,"indication":"Chronic Lymphocytic Leukemia","completionDate":""},{"nctId":"NCT00996593","phase":"Phase 2","title":"Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma Patients Who Have Previously Received Rituximab","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":43,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2009-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}